Simple Summary In this review, we examined relevant clinical trial results with immune
checkpoint inhibitors in patients with metastatic urothelial cancer. We also focused on the …

The world of molecular profiling has undergone revolutionary changes over the last few
years as knowledge, technology, and even standard clinical practice have evolved. Broad …

The efficacy of immunotherapy varies widely among different gastrointestinal cancers.
Response to immune checkpoint inhibitors is shown to correlate with tumor mutation load …

The treatment of bladder cancer has evolved over time to encompass not only the traditional
modalities of chemotherapy and surgery, but has been particularly impacted by the use of …

Bladder cancer is an important public health concern owing to its prevalence, high
recurrence risk and treatment failures. Maintaining the equilibrium between prompt and …

Cancers arising from the bladder urothelium often exhibit lineage plasticity with regions of
urothelial carcinoma adjacent to or admixed with regions of divergent histomorphology, most …

Simple Summary Urothelial bladder cancer (BC) is one of the most fatal cancers, with a
dismal five-year survival rate of 5% in patients with metastatic disease. Clinically relevant …

Purpose: On the basis of preclinical evidence of epigenetic contribution to sensitivity and
resistance to immune checkpoint inhibitors (ICI), we hypothesized that guadecitabine …

Causal analysis for time series data, in particular estimating individualized treatment effect
(ITE), is a key task in many real world applications, such as finance, retail, healthcare, etc …

Urinary bladder cancer is a common malignancy, being characterized by substantial patient
mortality and management cost. Its high somatic-mutation frequency and molecular …